Perspective Therapeutics to present ASCO 2026 data for next-gen radiopharmaceuticals
The company will release close look at Phase 1/2a data for its 212Pb-based candidates targeting NETs and melanoma. These data, detailing efficacy and safety, could draw investor attention to the pipeline's potential to address unmet needs in solid tumors.
View filing at SEC.gov →